Elicio Therapeutics, Inc.
ELTX
$2.18
-$0.17-7.23%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 17.28% | 29.99% | 35.96% | -4.15% | 12.43% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.35% | -1.25% | -34.39% | -22.23% | -7.63% |
| Operating Income | -3.35% | 1.25% | 34.39% | 22.23% | 7.63% |
| Income Before Tax | 22.19% | -5.48% | 44.89% | 46.48% | -46.09% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 22.19% | -5.48% | 44.89% | 46.48% | -46.09% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 22.19% | -5.48% | 44.89% | 46.48% | -46.09% |
| EBIT | -3.35% | 1.25% | 34.39% | 22.23% | 7.63% |
| EBITDA | -3.54% | 1.19% | 34.34% | 22.14% | 7.43% |
| EPS Basic | 35.07% | 24.99% | 51.49% | 56.45% | -2.65% |
| Normalized Basic EPS | 37.52% | 25.01% | 51.48% | 56.45% | -6.69% |
| EPS Diluted | 35.07% | 24.99% | 51.49% | 56.45% | -2.65% |
| Normalized Diluted EPS | 37.52% | 25.01% | 51.48% | 56.45% | -6.69% |
| Average Basic Shares Outstanding | 19.83% | 40.62% | 13.60% | 22.90% | 42.31% |
| Average Diluted Shares Outstanding | 19.83% | 40.62% | 13.60% | 22.90% | 42.31% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |